ORG-43902

ORG-43902, written in the scientific literature as Org 43902, is a low-molecular-weight agonist of the luteinizing hormone receptor, a G-protein-coupled receptor that normally responds to the pituitary hormone LH and to the placental hormone human chorionic gonadotropin (hCG) ^[1]. Those endogenous activators are large glycoprotein molecules that must be injected, whereas ORG-43902 belongs to a class of small synthetic compounds, built on a thieno-pyrimidine chemical scaffold, that were designed to reproduce the hormone's action in a form suitable for oral use ^[3][4].

The compound emerged from a drug-discovery program at Organon, a Dutch pharmaceutical company later absorbed into larger firms, which produced a pair of orally active low-molecular-weight LH agonists, Org 43553 and Org 43902 ^[1]. Much of the detailed pharmacological characterization of this class was carried out on the closely related prototype Org 43553, while ORG-43902 was advanced as a second candidate from the same series ^[2][3].

The intended application was ovulation induction, a step in fertility treatment that conventionally relies on injected hCG to prompt the release of an egg from a mature follicle ^[1]. In a first-in-human, randomized, placebo-controlled study in healthy female volunteers, a single oral dose of ORG-43902 was reported to be safe and well tolerated, to be absorbed quickly with peak blood levels reached within about an hour, and to have an elimination half-life on the order of a day; crucially, it induced ovulation in the great majority of the women who received an effective amount, with an ovulation rate of roughly four in five ^[1]. This provided early proof of concept that an oral pill could accomplish what previously required a hormone injection.

Mechanistic studies of this compound class, conducted largely with the sibling molecule Org 43553, showed that these agents do not compete with LH at the hormone's usual binding site but instead act allosterically, engaging a separate pocket within the receptor to switch on its signaling ^[2][3]. Reviews of low-molecular-weight agonists of the LH and related thyroid-stimulating hormone receptors have highlighted potential advantages of this approach over the natural glycoprotein hormones, including oral activity, low immunogenicity, chemical stability, and lower manufacturing cost ^[4].

Despite the encouraging early clinical result, ORG-43902 did not become a marketed drug and is best regarded as an investigational research compound. It illustrates a broader scientific effort to replace injectable glycoprotein hormones with orally available small molecules, an area that continues to attract interest in reproductive endocrinology ^[4].

In its Phase 1 trial (in women) it was considered safe and well tolerated. Compared with HCG it has real theoretical advantages: it is oral rather than injected, a stable small molecule rather than a bulky protein needing strict storage, and its shorter half-life gives the LH receptor more downtime during sleep. That downtime matters, because prolonged LH-receptor stimulation is toxic to Leydig cells; the cAMP pathway raises oxidative stress, and under those conditions StAR can shuttle a hydroperoxide into the mitochondria and cause damage. Downsides: the extra testosterone can convert to estrogen, so estradiol needs watching; human data are limited to one Phase 1 study in women; long-term effects are not yet established the way HCG's are; and it is price-comparable to HCG due to synthesis cost. Not medical advice.